Phase III
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
Episodes
7 episodes since 2024
NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals
In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment sched...
September 10, 2024
•
Season 2
•
Episode 2
•
29:47
NUKED: Why radiopharmaceuticals are exploding, with Peter MacCallum Cancer Centre and HB Biotechnology
The radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are in very, very short supply. Major clinical trials are hitting paus...
September 03, 2024
•
Season 2
•
Episode 1
•
25:34
The Silent Killer: The sci-fi episode
Wearable kidneys. Organs on a chip. Xenotransplantation. The future is here.But is that the future people in biotech are truly looking to? Because the future that Certa Therapeutics CEO Darren Kelly is looking to is much less 1980s sci-...
August 27, 2024
•
Season 1
•
Episode 4
•
27:59
The Silent Killer: Prevention is the next cure
We may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to bring medical sectors -- and governments -- along as well. ...
August 20, 2024
•
Season 1
•
Episode 3
•
23:06
The Silent Killer: Who has the killer apps?
We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS).And we talk to PYC T...
August 13, 2024
•
Season 1
•
Episode 2
•
24:40
The Silent Killer: Why biotechs are all in on kidney disease
Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done. But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in...
August 06, 2024
•
Season 1
•
Episode 1
•
26:54